Tiespectus + Aflibercept for Age-Related Macular Degeneration

(MALBEC Trial)

This trial tests a new medicine, tiespectus, to determine its effectiveness in treating neovascular age-related macular degeneration (NVAMD), a serious eye condition that can lead to vision loss. Researchers aim to compare tiespectus with aflibercept, a current standard treatment. Participants will receive either a low or high dose of tiespectus or the usual treatment with aflibercept. Ideal candidates for this trial are those recently diagnosed with NVAMD who have not yet received treatment. As a combined Phase 2 and Phase 3 trial, this study evaluates tiespectus in a smaller group and represents the final step before FDA approval, offering participants a chance to contribute to advancing treatment options.

The trial information does not specify if you need to stop taking your current medications. However, it does mention that participants should not have received certain eye treatments before joining the study.

Research has shown that tiespectus, the medicine being tested, was well-tolerated in earlier studies. One study on macular edema reported no serious eye-related or overall health issues. Additionally, there were no dose-limiting toxicities, indicating that participants could safely receive the treatment without harm. This suggests that tiespectus has a good safety record so far. While this information is encouraging, further research is needed to confirm these findings for age-related macular degeneration treatments.¹²³⁴⁵

Researchers are excited about Tiespectus for age-related macular degeneration because it offers a potentially new mechanism of action compared to existing treatments. While standard treatments like Aflibercept primarily inhibit a protein called VEGF to reduce abnormal blood vessel growth in the eye, Tiespectus may work on different or additional pathways, potentially enhancing effectiveness or broadening the patient response. This trial is testing both low and high doses of Tiespectus, which could lead to more tailored treatment options for patients, depending on their individual needs.

Research has shown that tiespectus may help treat eye conditions like macular edema, which resembles NVAMD. In earlier studies, tiespectus improved vision and reduced retinal swelling, both crucial for eye health. Tiespectus targets two key areas: it activates a protein that maintains healthy blood vessels and blocks signals that cause abnormal blood vessel growth. This dual action may help prevent vision loss and improve symptoms. In this trial, participants will receive either a low or high dose of tiespectus, or aflibercept as a comparator. While more research is needed to confirm its effectiveness for NVAMD specifically, these early results are promising.¹²⁶⁷⁸